Clee Medical, a Swiss neurotechnology startup developing novel ultra-high-resolution real-time imaging for brain surgery, today announced the successful closing of its Seed financing round. With the Seed financing, Clee Medical plans to expand its development and clinical programs and advance toward key milestones required for early clinical adoption, specifically their first in human clinical study. .

Clee Medical是一家瑞士神经技术初创公司，致力于开发用于脑外科手术的新型超高分辨率实时成像技术，该公司今天宣布成功完成了其种子轮融资。通过种子融资，Clee Medical计划扩展其研发和临床项目，并朝着早期临床应用所需的关键里程碑迈进，特别是他们的首次人体临床研究。

The financing will enable Geneva-based

这笔融资将使总部位于日内瓦的公司能够

Clee Medical

克利医疗

to accelerate the development and clinical validation of its Neuro Access platform, a minimally invasive technology designed to help neurosurgeons visualize brain anatomy and critical structures in real time during stereotactic procedures.

加速其神经介入平台的开发和临床验证，这是一种微创技术，旨在帮助神经外科医生在立体定向手术过程中实时可视化大脑解剖结构和关键组织。

“Neurosurgery still relies heavily on pre-operative imaging, while the reality in the operating room is dynamic and uncertain,” said Matthew Lapinski, Co-Founder and CEO of Clee Medical. “This Seed round allows us to bring a new level of real-time visibility into the brain, supporting safer procedures and expanding what minimally invasive neurosurgery can achieve.”.

“神经外科手术仍然严重依赖术前成像，而手术室中的现实是动态且不确定的，”Clee Medical联合创始人兼首席执行官马修·拉平斯基表示。“这次种子轮融资使我们能够为大脑提供一个全新水平的实时可视化支持，助力更安全的手术，并拓展微创神经外科手术的可能。”

Improving surgical precision in a high-risk environment

提高高风险环境中的手术精确度

Many neurosurgical procedures depend on navigating delicate brain structures with millimeter-level precision. Yet during surgery, anatomical shifts and limited intraoperative visibility can make targeting challenging. Clee Medical’s Neuro Access platform is designed to address this gap by providing real-time, ultra-high-resolution imaging inside the brain, supporting surgeons in navigating complex anatomy with greater confidence..

许多神经外科手术依赖于以毫米级精度导航精细的脑部结构。然而，在手术过程中，解剖结构的移位和有限的术中可见性可能会使目标定位变得困难。Clee Medical的Neuro Access平台旨在通过提供大脑内部的实时超高分辨率成像来弥补这一差距，帮助外科医生更加自信地导航复杂的解剖结构。

The company’s technology builds on years of translational research and is being developed with the goal of supporting a wide range of applications, including functional neurosurgery and neuro-oncology.

该公司技术建立在多年的转化研究基础上，正以支持包括功能性神经外科和神经肿瘤学在内的广泛应用为目标进行开发。

Funding will accelerate clinical validation and regulatory progress

资金将加速临床验证和监管进展。

With the Seed financing, Clee Medical plans to expand its development and clinical programs and advance toward key milestones required for early clinical adoption, specifically their first in human clinical study. The round was led by High-Tech Gründerfonds (

通过种子轮融资，Clee Medical计划扩展其开发和临床项目，并朝着早期临床应用所需的关键里程碑迈进，特别是他们的首次人体临床研究。本轮融资由High-Tech Gründerfonds领投。

HTGF

高特福

), one of Europe’s most active early-stage investors, with participation from Zürcher Kantonalbank (

），欧洲最活跃的早期投资者之一，苏黎世州银行（Zürcher Kantonalbank）也参与其中（

ZKB

苏黎世商业银行

),

),

Kickfund

踢基金

,

，

FONGIT

方吉特

, and

，以及

Venture Kick

风险投资启动

. The company also benefits from the continued participation from their existing partner and investor,

公司还受益于现有合作伙伴和投资者的持续参与，

Wyss Geneva

怀斯日内瓦

.

。

“Clee Medical is addressing a critical unmet need in neurosurgery: the ability to see relevant structures in real time during minimally invasive procedures,” said Tilmann Petersen, Investment Manager at HTGF. “We are glad to back such an experienced team — proven through the development and successful exits of today’s market‑standard neurosurgical devices such as the Stealth Station — and believe they have the technical depth and clinical focus to build a category‑defining platform in neurotechnology.”.

“Clee Medical正在解决神经外科领域一个关键的未满足需求：在微创手术过程中实时查看相关结构的能力，” HTGF的投资经理蒂尔曼·彼得森表示。“我们很高兴能够支持这样一个经验丰富的团队——他们通过开发当今市场标准的神经外科设备（如Stealth Station）并成功退出而得到验证——并且相信他们拥有构建神经技术领域定义性平台所需的技术深度和临床专注。”

A milestone for Swiss neurotechnology innovation

瑞士神经技术创新的里程碑

The Seed round marks a major step in Clee Medical’s transition from preclinical development into clinical translation. Supported by a strong European investor syndicate and the continued backing of Wyss Geneva, the company is positioned to advance Neuro Access toward real-world use in the operating room..

种子轮融资标志着Clee Medical从临床前开发向临床转化迈出的重要一步。在强大的欧洲投资者财团的支持以及Wyss Geneva的持续支持下，该公司有望推动Neuro Access走向在手术室中的实际应用。

Clee Medical’s long-term vision is to enable a future where neurosurgeons can operate with enhanced real-time insight, improving safety, efficiency, and outcomes for patients undergoing complex brain procedures.

Clee Medical的长期愿景是让神经外科医生能够在增强的实时洞察下进行手术，从而提高接受复杂脑部手术患者的安全性、效率和治疗效果。

The company is led by co-founders Matt Lapinski and Abed Hammoud. Matt brings more than a decade of experience building and scaling Class III medical device startups in the United States. Abed has contributed to the development of market-leading neurosurgical systems, including Medtronic’s StealthStation stereotactic platform and Renishaw’s NeuroMate robotic system, bringing deep expertise in precision neurotechnology and surgical navigation..

公司由联合创始人马特·拉平斯基 (Matt Lapinski) 和阿贝德·哈穆德 (Abed Hammoud) 领导。马特拥有十多年的从业经验，曾在美国创建和发展第三类医疗器械初创公司。阿贝德参与了市场领先的神经外科系统开发工作，包括美敦力的StealthStation立体定向平台和雷尼绍的NeuroMate机器人系统，带来了在精密神经技术和手术导航方面的深厚专业知识。

(PR)

公共关系

The Clee Medical founding team (from left): Gary Evans (principal engineer), Jules Scholler (optical systems engineer), Matt Lapinski (CEO) and Abed Hammoud (CTO)

Clee Medical创始团队（从左至右）：Gary Evans（首席工程师）、Jules Scholler（光学系统工程师）、Matt Lapinski（首席执行官）和Abed Hammoud（首席技术官）。

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送